{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:27:48Z","timestamp":1768778868488,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"FONDAZIONE ANNA MARIA SECHI PER IL CUORE"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00392-019-01547-2","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T17:03:11Z","timestamp":1568739791000},"page":"599-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["ARNIs: balancing \u201cthe good and the bad\u201d of neuroendocrine response to HF"],"prefix":"10.1007","volume":"109","author":[{"name":"the \u201cItalian-Portuguese Action on Heart Failure\u201d Group","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-9175","authenticated-orcid":false,"given":"Roberto","family":"Ferrari","sequence":"first","affiliation":[]},{"given":"J.","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"M. C.","family":"Fonseca","sequence":"additional","affiliation":[]},{"given":"C.","family":"Aguiar","sequence":"additional","affiliation":[]},{"given":"J. I.","family":"Moreira","sequence":"additional","affiliation":[]},{"given":"A.","family":"Fucili","sequence":"additional","affiliation":[]},{"given":"C.","family":"Rapezzi","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"issue":"27","key":"1547_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129\u20132200. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"issue":"6","key":"1547_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70(6):776\u2013803. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2017.04.025","journal-title":"J Am Coll Cardiol"},{"key":"1547_CR3","doi-asserted-by":"publisher","unstructured":"Jobs A, Abdin A, de Waha-Thiele S, Eitel I, Thiele H, de Wit C, Vonthein R (2019) Angiotensin-converting-enzyme inhibitors in hemodynamic congestion: a meta-analysis of early studies. Clin Res Cardiol. \nhttps:\/\/doi.org\/10.1007\/s00392-019-01456-4\n\n. (Epub ahead of print] (PMID: 30895374))","DOI":"10.1007\/s00392-019-01456-4"},{"key":"1547_CR4","doi-asserted-by":"publisher","unstructured":"Ohtani K, Ide T, Hiasa KI, Sakamoto I, Yamashita N, Kubo M, Tsutsui H (2019) Cardioprotective effect of renin-angiotensin inhibitors and \u03b2-blockers in trastuzumab-related cardiotoxicity. Clin Res Cardiol. \nhttps:\/\/doi.org\/10.1007\/s00392-019-01448-4\n\n. ([Epub ahead of print] PMID: 30859381)","DOI":"10.1007\/s00392-019-01448-4"},{"issue":"8811","key":"1547_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0140-6736(92)90405-R","volume":"340","author":"M Packer","year":"1992","unstructured":"Packer M (1992) Pathophysiology of chronic heart failure. Lancet (Lond Engl) 340(8811):88\u201392","journal-title":"Lancet (Lond Engl)"},{"issue":"11","key":"1547_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"1547_CR7","doi-asserted-by":"publisher","unstructured":"Martens P, Nuyens D, Rivero-Ayerza M, Van Herendael H, Vercammen J, Ceyssens W, Luwel E, Dupont M, Mullens W (2019) Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol. \nhttps:\/\/doi.org\/10.1007\/s00392-019-01440-y\n\n. ([Epub ahead of print] (PMID: 30788621))","DOI":"10.1007\/s00392-019-01440-y"},{"issue":"5","key":"1547_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","volume":"5","author":"JP Seferovic","year":"2017","unstructured":"Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD (2017) Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5(5):333\u2013340. \nhttps:\/\/doi.org\/10.1016\/S2213-8587(17)30087-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"38","key":"1547_CR9","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","volume":"36","author":"PS Jhund","year":"2015","unstructured":"Jhund PS, Fu M, Bayram E, Chen C-H, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJV, Packer M, PARADIGM-HF Investigators Committees (2015) Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J 36(38):2576\u20132584. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehv330","journal-title":"Eur Heart J"},{"issue":"6","key":"1547_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","volume":"6","author":"K Damman","year":"2018","unstructured":"Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 6(6):489\u2013498. \nhttps:\/\/doi.org\/10.1016\/j.jchf.2018.02.004","journal-title":"JACC Heart Fail"},{"issue":"7","key":"1547_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","volume":"6","author":"M Packer","year":"2018","unstructured":"Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR (2018) Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol 6(7):547\u2013554. \nhttps:\/\/doi.org\/10.1016\/S2213-8587(18)30100-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1547_CR12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ejhf.548","volume":"18","author":"M Senni","year":"2016","unstructured":"Senni M, McMurray JJV, Wachter R, McIntyre HF, Reyes A, Majercak I, Andreka P, Shehova-Yankova N, Anand I, Yilmaz MB, Gogia H, Martinez-Selles M, Fischer S, Zilahi Z, Cosmi F, Gelev V, Galve E, G\u00f3mez-Doblas JJ, Nociar J, Radomska M, Sokolova B, Volterrani M, Sarkar A, Reimund B, Chen F, Charney A (2016) Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail 18(9):1193\u20131202. \nhttps:\/\/doi.org\/10.1002\/ejhf.548","journal-title":"Eur J Heart Fail"},{"key":"1547_CR13","unstructured":"Wachter R, Senni M, Belohlavek J, Butylin D, Noe A, Pascual-Figal D (2018) P886 initiation of sacubitril\/valsartan in hospitalized patients with heart failure with reduced ejection fraction after hemodynamic stabilisation: primary results of the TRANSITION study. Eur Heart J 39:ehy564\u2013886"},{"issue":"6","key":"1547_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, Investigators PIONEER-HF (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380(6):539\u2013548. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"issue":"9","key":"1547_CR15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"JJ McMurray","year":"2013","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Committees Investigators (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15(9):1062\u20131073. \nhttps:\/\/doi.org\/10.1093\/eurjhf\/hft052","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1547_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","volume":"68","author":"A Bayes-Genis","year":"2016","unstructured":"Bayes-Genis A, Barallat J, Richards AM (2016) A test in context: Neprylisin. Function, inhibition, and biomarker J Am Coll Cardiol 68(6):639\u2013653. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2016.04.060","journal-title":"Function, inhibition, and biomarker J Am Coll Cardiol"},{"issue":"11","key":"1547_CR17","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","volume":"278","author":"LR Potter","year":"2011","unstructured":"Potter LR (2011) Natriuretic peptide metabolism, clearance and degradation. FEBS J 278(11):1808\u20131817. \nhttps:\/\/doi.org\/10.1111\/j.1742-4658.2011.08082.x","journal-title":"FEBS J"},{"issue":"5","key":"1547_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1042\/cs0950547","volume":"95","author":"JG Lainchbury","year":"1998","unstructured":"Lainchbury JG, Nicholls MG, Espiner EA, Ikram H, Yandle TG, Richards AM (1998) Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man. Clin Sci (Lond) 95(5):547\u2013555","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"1547_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1677\/joe.0.1670239","volume":"167","author":"MW Smith","year":"2000","unstructured":"Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM (2000) Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 167(2):239\u2013246","journal-title":"J Endocrinol"},{"issue":"1\u20132","key":"1547_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cccn.2003.10.026","volume":"340","author":"A Belenky","year":"2004","unstructured":"Belenky A, Smith A, Zhang B, Lin S, Despres N, Wu AH, Bluestein BI (2004) The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 340(1\u20132):163\u2013172","journal-title":"Clin Chim Acta"},{"issue":"6","key":"1547_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrcardio.2014.56","volume":"11","author":"R Ferrari","year":"2014","unstructured":"Ferrari R (2014) Coronary artery disease: use of ACE inhibitors in stable CAD\u2014what is the truth? Nature Rev Cardiol 11(6):315\u2013316","journal-title":"Nature Rev Cardiol"},{"key":"1547_CR22","doi-asserted-by":"crossref","unstructured":"Ferrari R, Ceconi C (2012) Landmark Trials: PERTINENT Cardiovasc Res 96(2):204\u2013207","DOI":"10.1093\/cvr\/cvs165"},{"issue":"8","key":"1547_CR23","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 106(8):920\u2013926","journal-title":"Circulation"},{"issue":"9230","key":"1547_CR24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S0140-6736(00)02596-4","volume":"356","author":"FH Messerli","year":"2000","unstructured":"Messerli FH, Nussberger J (2000) Vasopeptidase inhibition and angio-oedema. Lancet 356(9230):608\u2013609","journal-title":"Lancet"},{"issue":"3","key":"1547_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/0306-4522(85)90156-3","volume":"14","author":"PK Mulderry","year":"1985","unstructured":"Mulderry PK, Ghatei MA, Rodrigo J, Allen JM, Rosenfeld MG, Polak JM, Bloom SR (1985) Calcitonin gene-related peptide in cardiovascular tissues of the rat. Neuroscience 14(3):947\u2013954","journal-title":"Neuroscience"},{"issue":"1","key":"1547_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0304-3940(85)90045-X","volume":"57","author":"J Hanko","year":"1985","unstructured":"Hanko J, Hardebo JE, Kahrstrom J, Owman C, Sandler F (1985) Calcitonin gene-related peptide is present in mammalian cerebrovascular nerve fibers and dilates pial and peripheral arteries. Neurosci Lett 57(1):91\u201395","journal-title":"Neurosci Lett"},{"issue":"11","key":"1547_CR27","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/cvr\/24.11.938","volume":"24","author":"G Agnoletti","year":"1990","unstructured":"Agnoletti G, Cornacchiari A, Panzali AF, Ghielmi S, De Giuli F, Ferrari R (1990) Effect of congestive heart failure on rate of atrial natriuretic factor release in response to stretch and isoprenaline. Cardiovasc Res 24(11):938\u2013945","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1547_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0735-1097(91)90729-S","volume":"17","author":"IS Anand","year":"1991","unstructured":"Anand IS, Gurden J, Wander GS, O\u2019Gara P, Harding SE, Ferrari R, Cornacchiari A, Panzali A, Wahi PL, Poole-Wilson PA (1991) Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure. J Am Coll Cardiol 17(1):208\u2013217","journal-title":"J Am Coll Cardiol"},{"issue":"6236","key":"1547_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/340721a0","volume":"340","author":"K Ona","year":"1989","unstructured":"Ona K, Delay M, Nakajima T, Irisawa H, Giles W (1989) Calcitonin generated peptide regulates calcium current in heart muscle. Nature 340(6236):721\u2013724","journal-title":"Nature"},{"issue":"3 Pt 2","key":"1547_CR30","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1164\/ajrccm\/143.3_Pt_2.S33","volume":"143","author":"JA Nadel","year":"1991","unstructured":"Nadel JA, Borson DB (1991) Modulation of neurogenic inflammation by neutral endopeptidase. Am Rev Respir Dis 143(3 Pt 2):S33\u201336","journal-title":"Am Rev Respir Dis"},{"key":"1547_CR31","unstructured":"Spillantini MG, Sicuteri F, Salmon S, Malfroy B (1990) Characterization of endopeptidase 3.4.24.11 (\u201cenkephalinase\u201d) activity in human plasma and cerebrospinal fluid. Biochem Pharmacol 39(8):1353\u20131356"},{"key":"1547_CR32","unstructured":"Roques BP, Noble F, Daug\u00e9 V, Fourni\u00e9-Zaluski MC, Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45(1):87\u2013146"},{"issue":"15","key":"1547_CR33","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/eurheartj\/ehv015","volume":"36","author":"N Vodovar","year":"2015","unstructured":"Vodovar N, Paquet C, Mebazaa A, Launay JM, Hugon J, Cohen-Solal A (2015) Neprilysin, cardiovascular, and Alzheimer\u2019s diseases: the therapeutic split? Eur Heart J 36(15):902\u2013905. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehv015","journal-title":"Eur Heart J"},{"key":"1547_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fnagi.2013.00098","volume":"5","author":"MO Grimm","year":"2013","unstructured":"Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T (2013) Neprilysin and Ab clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer\u2019s disease. Front Aging Neurosci 5:98. \nhttps:\/\/doi.org\/10.3389\/fnagi.2013.00098","journal-title":"Front Aging Neurosci"},{"issue":"41","key":"1547_CR35","doi-asserted-by":"publisher","first-page":"30471","DOI":"10.1074\/jbc.M605827200","volume":"281","author":"EA Eckman","year":"2006","unstructured":"Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KE, Eckman CB (2006) Regulation of steady-state b-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 281(41):30471\u201330478","journal-title":"J Biol Chem"},{"issue":"2","key":"1547_CR36","doi-asserted-by":"publisher","first-page":"G544","DOI":"10.1152\/ajpgi.2001.281.2.G544","volume":"281","author":"KS Kirkwood","year":"2001","unstructured":"Kirkwood KS, Bunnett NW, Maa J, Castagliolo I, Liu B, Gerard N, Zacks J, Pothoulakis C, Grady EF (2001) Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile toxin A. Am J Physiol Gastrointest Liver Physiol 281(2):G544\u2013G551","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1547_CR37","doi-asserted-by":"publisher","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Mor\u00f3n FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fi\u00e9vet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuiness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Boss\u00f9 P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F (2013) European Alzheimer's Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease; Alzheimer's Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltuenen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, N\u00f6then MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P (2018) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet 45(12):1452\u20131458. \nhttps:\/\/doi.org\/10.1038\/ng.2802","DOI":"10.1038\/ng.2802"},{"issue":"2","key":"1547_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1067\/msy.2000.107378","volume":"128","author":"J Maa","year":"2000","unstructured":"Maa J, Grady EF, Yoshimi SK, Drasin TE, Kim EH, Hutter MM, Bunnett NW, Kirkwood KS (2000) Substance P is a determinant of lethality in diet-induced hemorrhagic pancreatitis in mice. Surgery 128(2):232\u2013239","journal-title":"Surgery"},{"issue":"8593","key":"1547_CR39","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(88)91852-1","volume":"1","author":"P Harris","year":"1988","unstructured":"Harris P (1988) Role of arterial pressure in the oedema of heart disease. Lancet 1(8593):1036\u20131038","journal-title":"Lancet"},{"issue":"2","key":"1547_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/clinchem\/35.2.331","volume":"35","author":"R Ferrari","year":"1989","unstructured":"Ferrari R, Ceconi C, Signorini C, Arnand I, Harris P, Albertini A (1989) Sample treatment for long-distance transport of plasma for hormone assay. Clin Chem 35(2):331\u2013332","journal-title":"Clin Chem"},{"key":"1547_CR41","doi-asserted-by":"publisher","unstructured":"Stienen S, Rossignol P, Barros A, Girerd N, Pitt B, Zannad F, Ferreira JP (2019) Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS) and early eplerenone treatment in patients with acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials. Clin Res Cardiol. \nhttps:\/\/doi.org\/10.1007\/s00392-019-01500-3\n\n. ([Epub ahead of print] (PMID: 31250134))","DOI":"10.1007\/s00392-019-01500-3"},{"key":"1547_CR42","doi-asserted-by":"publisher","unstructured":"Ferreira JP, Pizard A, Machu JL, Bresso E, Rocca HB, Girerd N, Leroy C, Gonz\u00e1lez A, Diez J, Heymans S, Devignes MD, Rossignol P, Zannad F (2019) Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses. Clin Res Cardiol. \nhttps:\/\/doi.org\/10.1007\/s00392-019-01480-4\n\n. ([Epub ahead of print] (PMID: 31062082))","DOI":"10.1007\/s00392-019-01480-4"},{"key":"1547_CR43","doi-asserted-by":"publisher","unstructured":"M\u00fcnzel T, Hahad O, Gori T, Hollmann S, Arnold N, Prochaska JH, Schulz A, Beutel M, Pfeiffer N, Schmidtmann I, Lackner KJ, Keaney JF, Wild PS (2019) Heart rate, mortality, and the relation with clinical and subclinical cardiovascular diseases: results from the Gutenberg Health Study. Clin Res Cardiol. \nhttps:\/\/doi.org\/10.1007\/s00392-019-01466-2\n\n. ([Epub ahead of print] PMID: 30953178)","DOI":"10.1007\/s00392-019-01466-2"},{"key":"1547_CR44","unstructured":"Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris P (1989) Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 80(2):299\u2013305"},{"issue":"1","key":"1547_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/01.CIR.86.1.12","volume":"86","author":"IS Anand","year":"1992","unstructured":"Anand IS, Chandrashekhar Y, Ferrari R, Sarma R, Guleria R, Jindal SK, Wahi PL, Poole-Wilson PA, Harris PC (1992) Pathogenesis of the congestive state in chronic obstructive pulmonary disease: studies of body water and sociium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation 86(1):12\u201321","journal-title":"Circulation"},{"issue":"3","key":"1547_CR46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0022-2828(87)80588-6","volume":"19","author":"G Agnoletti","year":"1987","unstructured":"Agnoletti G, Rodella A, Ferrari R, Harris P (1987) Release of atrial natriuretic peptide-like immunoreactive material during stretchin of the rat atrium in vitro. J Mol Cell Cardiol 19(3):217\u2013220","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"1547_CR47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000445882","volume":"135","author":"R Ferrari","year":"2016","unstructured":"Ferrari R, Malag\u00f9 M, Biscaglia S, Fucili A, Rizzo P (2016) Remodelling after an Infarct: crosstalk between life and death cardiology. Cardiology 135(2):68\u201376. \nhttps:\/\/doi.org\/10.1159\/000445882","journal-title":"Cardiology"},{"issue":"1","key":"1547_CR48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, B\u011blohl\u00e1vek J, B\u00f6hm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonz\u00e0lez-Medina A, Hag\u00e8ge AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan \u00d6, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC, PARADIGM-HF Investigators Coordinators (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131(1):54\u201361. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013748","journal-title":"Circulation"},{"issue":"6","key":"1547_CR49","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1161\/01.CIR.83.6.1880","volume":"83","author":"IS Anand","year":"1991","unstructured":"Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC (1991) Pathogenesis of edema in constrictive pericarditis: studies of body water and sodium, renal function, hemodynamics and plasma hormones before and after pericardiectomy. Circulation 83(6):1880\u20131887","journal-title":"Circulation"},{"issue":"11","key":"1547_CR50","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.jacc.2005.03.050","volume":"45","author":"FS Leya","year":"2005","unstructured":"Leya FS, Arab D, Joyal D, Shioura KM, Lewis BE, Steen LH, Cho L (2005) The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 45(11):1900\u20131902","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1547_CR51","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/0002-8703(89)90264-0","volume":"118","author":"IS Anand","year":"1989","unstructured":"Anand IS, Kalra GS, Ferrari R, Wahi PL, Poole-Wilson PA, Harris P (1989) Haemodynamic, hormonal, and renal effects of alpha-human ANP infusion in untreated congested heart failure. Am Heart J 118(3):500\u2013505","journal-title":"Am Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01547-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-019-01547-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01547-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T23:06:59Z","timestamp":1600211219000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-019-01547-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1547"],"URL":"https:\/\/doi.org\/10.1007\/s00392-019-01547-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"9 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RF has received honoraria for steering committee membership and consulting from Novartis and Servier; and speaker fees from Cipla, Lupin, Merck Serono, and Servier International. JC has consulted and received speaker fees, or investigational grants for Abbott, AstraZeneca Pharmaceuticals, Bial, Boehringer Ingelheim, Menarini, Merck Serono, Merck Sharp & Dohme, Novartis, Orion, Pfizer, Sanofi and Vifor M.C.F. has received fees from Novartis, Servier,Orion, Roche, Bayer and Vifor (companies that develop and market tests and\/or treatments in the area of HF) for HF consulting, sitting on clinical study steering committees and giving lectures at congresses and other scientific sessions. CA has received lecture fees and honoraria for consultancy from Novartis and Servier. JIM has no conflict of interest. DM has no conflict of interest. CR has received honoraria (as a speaker and board member) from Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}